U.S. Department of Defense Awards UT and Moderna $25M Contract for mRNA Vaccine Development
January 12, 2023
Trending News ☀️
Moderna ($NASDAQ:MRNA) is a leading biotechnology company that focuses on the development of transformative medicines through the use of messenger RNA (mRNA) technology. The U.S. Department of Defense (DoD) has awarded the University of Texas (UT) a contract worth up to $25 million for a collaborative effort with Moderna to create vaccines against Ebola and other biological threats using Moderna’s mRNA technology. This contract is designed to further the development of vaccines in the fight against pandemics and other emerging biologic threats. The partnership between UT and Moderna will utilize Moderna’s mRNA technology to develop vaccines for a range of potential biologic threats, including Ebola, Marburg, Lassa Fever, and MERS-CoV. The contract will also fund the development of a platform for rapid response to emerging biologic threats by leveraging UT’s expertise in vaccine development, molecular design, and vaccine validation.
This will allow the DoD to quickly mobilize resources to respond to an emerging threat, as well as create a framework for future vaccine development. The DoD is confident that this collaboration between UT and Moderna will bring new and innovative solutions to the fight against pandemics and other biologic threats. The partnership will also provide UT researchers with access to Moderna’s mRNA technology and accelerate the development of vaccines that could save lives in the future. This is an important step forward in the fight against pandemics, and the DoD is committed to investing in the development of new treatments and technologies.
Share Price
This contract is part of a larger effort to find a safe and effective vaccine against the disease. The news of the contract has been met with largely negative media sentiment. Moderna‘s stock opened on Wednesday at $188.6 and closed at $186.6, down by 1.6% from the previous closing price of $189.6. This decrease in stock price could be attributed to the uncertainty in the success of the vaccine development, as well as its potential timeline. Moderna is a biotechnology company based in Cambridge, Massachusetts that specializes in the development of mRNA-based medicines.
It has been at the forefront of developing a vaccine using their mRNA-based platform, which has shown promising results in early clinical trials. The funding will be used to cover the costs of research and development, as well as clinical trials and manufacturing of the vaccine. With the support of the U.S. Department of Defense, it is possible that an mRNA-based vaccine could be available as soon as next year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Moderna. More…
| Total Revenues | Net Income | Net Margin |
| 20.68k | 11.77k | 57.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Moderna. More…
| Operations | Investing | Financing |
| 6.63k | -5.27k | -3.88k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Moderna. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 26.06k | 8.06k | 46.49 |
Key Ratios Snapshot
Some of the financial key ratios for Moderna are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 565.0% | – | 64.6% |
| FCF Margin | ROE | ROA |
| 30.0% | 46.4% | 32.0% |
VI Analysis
Moderna is a high risk investment according to the VI Risk Rating. This rating is a summary of the company’s fundamentals and reflects its long term potential. The VI App has detected 4 risk warnings in the balance sheet, cash flow statement, non-financial and financial journals of Moderna. These warnings could be indicators of potential issues that could affect the company’s overall performance. The balance sheet risk warning points out that the company’s current assets are not enough to cover its liabilities. This could lead to liquidity issues and cash flow problems. The cash flow statement warning suggests that Moderna is having difficulty generating cash to cover its current expenses. The non-financial risk warning signals that there may be issues with the company’s operations, such as lack of innovation or mismanagement of resources. Lastly, the financial journal warning points to potential issues with the company’s accounting practices. Overall, Moderna is a high risk investment due to its current financial and business fundamentals. It is important for potential investors to take these warnings into consideration before making a decision. Investors can become a registered user to analyze the company’s risk warnings more in-depth. More…
VI Peers
Moderna Inc is a biotechnology company that develops and manufactures drugs, vaccines, and diagnostics. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. Moderna Inc’s main competitors are BioNTech SE, Pfizer Inc, and Novavax Inc.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 33.72B as of 2022 and a Return on Equity of 71.82%. BioNTech focuses on the development of innovative therapies for the treatment of cancer and other diseases. The company’s most advanced product is a vaccine for the treatment of human papillomavirus (HPV). BioNTech is also developing a number of other vaccines and therapies for the treatment of cancer, infectious diseases, and autoimmune disorders.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a global pharmaceutical company with a market cap of 247.45B as of 2022. The company’s return on equity is 24.63%. Pfizer’s products include prescription and over-the-counter medicines, vaccines, and animal health products. The company operates in over 150 countries and serves patients and customers across the globe.
– Novavax Inc ($NASDAQ:NVAX)
Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Novavax’s market cap as of 2022 is 1.46B and its ROE is 487.21%. The company’s lead product candidates are NVX-CoV2373, which is in Phase III clinical trials for the prevention of COVID-19, and ResVax, which is in Phase III clinical trials for the prevention of respiratory syncytial virus (RSV) disease.
Summary
Moderna Inc. is a biotechnology company that has recently been awarded a $25 million contract by the US Department of Defense to develop an mRNA vaccine. However, the potential rewards are high due to the potential for a successful product to revolutionize the biopharmaceutical industry. Moderna’s stock is currently trading at a high price-to-earnings ratio and has experienced a significant surge in its share value over the past year. Investors should carefully consider the risks and rewards associated with investing in Moderna before making any decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
